The frequency that multiple different subtypes of hepatitis C virus (HCV) simultaneously infect a given individual is controversial. To address this question, heteroduplex mobility analysis (HMA) of portions of the HCV core and envelope 1 region was optimized for sensitive and specific detection of mixtures of HCV genomes of different genotype or subtype. Using the standard HCV genotyping approach of 5-untranslated region (UTR) analysis, 28 of 374 (7.5%) chronic hepatitis C research subjects were classified as having either multiple-subtype HCV infections (n ‫؍‬ 21) or switching HCV subtypes over time (n ‫؍‬ 7), the latter pattern implying viral superinfection. Upon retesting of specimens by HMA, 25 of 28 multiple-subtype results could not be reproduced. All three patients with positive results were injection drug users with potential multiple HCV exposures. To address the hypothesis of tissue sequestration of multiple-subtype HCV infections, liver (n ‫؍‬ 22), peripheral blood mononuclear cell (n ‫؍‬ 13), perihepatic lymph node (n ‫؍‬ 16), and serum (n ‫؍‬ 19) specimens from 23 subjects with end-stage hepatitis C were collected and analyzed by the HMA technique. Whereas 5-UTR results implicated mixed-subtype HCV infections in 2 subjects, HMA testing revealed no evidence of a second HCV subtype in any tissue compartment (0 of 70 compartments [0%]) or within any given subject (0 of 23 subjects [0%]). In summary, a large proportion of mixed-genotype and switching-genotype patterns generated by 5-UTR analysis were not reproducible using the HMA approach, emphasizing the need for additional study.
The frequency that multiple different subtypes of hepatitis C virus (HCV) simultaneously infect a given individual is controversial. To address this question, heteroduplex mobility analysis (HMA) of portions of the HCV core and envelope 1 region was optimized for sensitive and specific detection of mixtures of HCV genomes of different genotype or subtype. Using the standard HCV genotyping approach of 5-untranslated region (UTR) analysis, 28 of 374 (7.5%) chronic hepatitis C research subjects were classified as having either multiple-subtype HCV infections (n ‫؍‬ 21) or switching HCV subtypes over time (n ‫؍‬ 7), the latter pattern implying viral superinfection. Upon retesting of specimens by HMA, 25 of 28 multiple-subtype results could not be reproduced. All three patients with positive results were injection drug users with potential multiple HCV exposures. To address the hypothesis of tissue sequestration of multiple-subtype HCV infections, liver (n ‫؍‬ 22), peripheral blood mononuclear cell (n ‫؍‬ 13), perihepatic lymph node (n ‫؍‬ 16), and serum (n ‫؍‬ 19) specimens from 23 subjects with end-stage hepatitis C were collected and analyzed by the HMA technique. Whereas 5-UTR results implicated mixed-subtype HCV infections in 2 subjects, HMA testing revealed no evidence of a second HCV subtype in any tissue compartment (0 of 70 compartments [0%]) or within any given subject (0 of 23 subjects [0%]). In summary, a large proportion of mixed-genotype and switching-genotype patterns generated by 5-UTR analysis were not reproducible using the HMA approach, emphasizing the need for additional study.
Hepatitis C virus (HCV), a plus-strand RNA virus classified within the Flaviviridae family, is a major cause of chronic liver disease, cirrhosis, end-stage liver disease, and hepatocellular carcinoma (10) . Data from prevalence studies have suggested that between 2.7 to 3.9 million people in the United States and approximately 170 million people worldwide have evidence of HCV infections (1, 2) . HCV-related disease is the most common indication for liver transplantation and one of the leading causes of liver-related death in the United States (34, 46, 48) .
Genetic heterogeneity is an outstanding feature of HCV and is known to influence important clinical aspects of infection, such as response to therapy and possibly outcome of infection (12, 13, 31, 32, 44) . Thus, accurate understanding of the scope of HCV heterogeneity during human infection has important medical implications. The HCV genome consists of highly conserved 5Ј-and 3Ј-untranslated regions (UTR) plus a larger and more variable genetic fragment encoding a single polyprotein precursor that is cleaved by cellular and viral proteases to yield the structural (core, envelope 1, and envelope 2) and nonstructural (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) HCV proteins (16) . Based on genetic data, HCV is classified into 6 major genotypes (or clades) and over 80 subgenotypes (or subtypes) (39, 40) . Genetic variation is not uniformly distributed among the various regions of the HCV genome (4, 18, 38, 40) . Genotypes 1, 2, and 3 account for the vast majority of HCV infections in the United States (20) and are the focus of the present study.
HCV also evolves as viral "quasispecies," a term used to describe a population of closely related yet genetically distinct viral variants derived from a common ancestor variant during chronic infection of an individual host (22, 47) . The genotype and subtype of all variants within a given individual do not change during chronic infection but require hundreds to thousands of years to diverge sufficient distance for classification as a discrete subtype (36, 37) . Multiple studies have demonstrated that different tissue reservoirs such as lymph nodes, brain, peripheral blood mononuclear cells, and liver may harbor different HCV genetic populations, suggesting that HCV may compartmentalize in vivo (14, 19, 21, 29, 30, 33) . Two recent studies have reported that a significant proportion of HCVinfected subjects are simultaneously coinfected with two or more different genotypes or subtypes that have distinctly different tissue distributions (11, 33) . If true, this finding has important implications for therapeutic design. For example, if a subject had genotype 2 or 3 in the blood, yet genotype 1 hidden in a different tissue reservoir, treatment with standard therapy for genotype 2/3 infections (a 6-month course of pegylated interferon plus ribavirin) might not work due to the relative resistance of genotype 1 infection to this regimen. The finding also has strong implications for the interpretation of data in all previous and subsequent studies examining the E2 gene hypervariable region 1 of HCV quasispecies.
Most HCV genotyping methods, including the one used in the abovementioned studies describing tissue sequestration of HCV subtypes, are based on PCR amplification and typespecific assay of the highly conserved 5Ј-UTR, either by direct sequencing (15, 25, 40, 41) , restriction fragment length polymorphism (RFLP) analysis (9, 24) , or line probe reverse hybridization assay (11, 21, 42, 43) . However, the above assays have two important limitations. By design, they discriminate different HCV genotypes based on only a single or at most a few nucleotide mutations within the 5Ј-UTR and are subject to misgenotyping due to spurious HCV mutations that occur in nature (4) . Furthermore, all 5Ј-UTR-based assays described above identify only predominant viral species and could easily miss nonpredominant variants comprising less than 10% of the total viral population. To overcome these two obstacles, we developed a heteroduplex mobility analysis (HMA) technique that uses HCV subtype-specific probes targeting portions of the HCV core and envelope 1 genes and is thus highly specific for discriminating HCV subtypes. The HMA assay is also sensitive enough to discriminate nonpredominant HCV variants from predominant variants present at a 1:100 ratio or lower. In the present study, the HMA technique was performed on a variety of serum and tissue samples from research subjects with chronic hepatitis C, to provide further information on the important question of human coinfection with mixtures of different HCV genotypes or subtypes.
MATERIALS AND METHODS
Patient samples and initial genotyping. For our field base cohort study of HCV mixed-genotype infections in serum, 769 serum samples were selected from 374 subjects enrolled in the cohort of Alaskan Natives and American Indians as part of an NIH-funded study with Institutional Review Board approval (23) . The research complied with all relevant federal guidelines and institutional policies. The 374 subjects were originally genotyped by 5Ј-RFLP analysis (9) , and specimens with either mixed-HCV-genotype results (n ϭ 21) or evidence of HCV genotype switching over time (n ϭ 7) were selected for further study using the HMA technique. For the samples from various tissue compartments, 23 subjects who were chronically infected with HCV and developed end-stage liver disease were recruited, and tissue samples were collected at the time of liver transplantation using a protocol approved by the University of Washington Institutional Review Board (30) . Serum samples and peripheral blood mononuclear cells (PBMCs) were purified, divided into aliquots, and stored at Ϫ80°C. Liver biopsy specimens and lymph node biopsy specimens were immediately snap-frozen at the bedside in optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA) and stored at Ϫ80°C. HCV genotypes of the subjects were initially determined by 5Ј-RFLP analysis using the serum sample (9) . In addition, 44 random clinical serum samples were genotyped by both HMA and direct sequencing of region E1 to prove method accuracy.
RNA extraction and RT-PCR. RNA was quantified by real-time PCR prior to extraction from sera or tissue-containing OCT buffer with the QIAamp viral RNA mini kit (Qiagen, Inc., Valencia, CA) or RNeasy mini kit (Qiagen, Inc., Valencia, CA) according to the manufacturer's instructions. Known positive and negative sera and water were included in all reactions from the extraction step as positive and negative controls. For reactions, 50,000 RNA copies were considered optimal, so that species present at concentrations of 1% or less (500 copies) could be reproducibly detected. The entire RNA sample was used when titers were below this level. The cDNA synthesis was carried out with 25-l reaction mixtures containing 10 l of RNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3 mM MgCl 2 , 0.6 mM dithiothreitol, 4 mM each deoxynucleoside triphosphate (dATP, dCTP, dGTP, and dTTP), 4 M antisense primer JBE1-1as (Table 1 ), 6 U of RNase inhibitor (Roche Applied Science, Indianapolis, IN), and 130 U of Moloney murine leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA). Reverse transcription (RT) was performed at 37°C for 1 h, and the reverse transcriptase was inactivated at 95°C for 5 min before proceeding to PCR amplification. The core/E1 region was amplified by two rounds of PCR, with the outer primers JBE1-1as (antisense primer, round I) and JBE1-1s (sense primer, round I) and inner primers JBE1-3as (antisense primer, round II) and JBE1-2s (sense primer, round II), as listed in Table 1 (5) . PCR was performed in a 50-l mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3 mM MgCl 2 , 0.8 mM each deoxynucleoside triphosphate, 0.5 M antisense and sense primers, 10 l of cDNA product or 1 l of PCR I product, and 1.5 U AmpliTaq polymerase (Roche Applied Science, Indianapolis, IN). Thermal cycling reactions were carried out with a GeneAmp PCR system 9600 (Perkin-Elmer, Applied Biosystems), consisting of 35 cycles of 94°C for 15 s, 45°C (round I), or 55°C (round II) for 30 s and extension at 72°C for 45 s. The second-round PCR products were separated on a 1.5% agarose gel, stained with ethidium bromide, and visualized under UV light. To perform sequencing, RT-PCR products were purified by QIAquick PCR purification kit (Qiagen, Inc., Valencia, CA) and subcloned into the TA cloning vector (Invitrogen, Carlsbad, CA). Recombinant plasmids were transformed into Escherichia coli Top10 competent cells (Invitrogen, Carlsbad, CA), and PCR-amplified fragments from single colonies were sequenced at both directions using an ABI 3730XL high-throughout capillary DNA analyzer.
Probe construction and probe labeling. HCV subtype-specific probes were generated from RT-PCR products of the core/E1 region derived from sera of individuals infected with known genotypes (1a, 1b, 2a, 2b, and 3a). RT-PCR products were purified and subcloned as described above, and plasmids isolated from single colonies were sequenced to confirm the genotype and subtype of the inserted fragments. Database searches were conducted with BLAST (3). Multiple alignments and calculation of evolutionary distances were carried out with Clustal W using the neighbor-joining method (45) . E. coli strains harboring genotype-and subtype-specific plasmids were stored in 15% glycerol in a Ϫ80°C freezer.
Subtype-specific probes were amplified by PCR with JBE1-3as and JBE1-2s primers using the plasmids containing HCV fragments as templates. Gel-purified probes were denatured at 95°C for 3 min in reaction buffer containing 70 mM Tris-HCl (pH 7.6), 10 mM MgCl 2 , 100 mM KCl, and 1 mM 2-mercaptoethanol and end labeled with [ Probe hybridization analysis.
32
P-labeled probes (1a, 1b, 2a, 2b, or 3a) were hybridized to a 50-to 100-fold molar excess of colinear PCR products of the core/E1 region derived from either the homologous standard or from research samples. Hybridization was carried out in a 16-l reaction system consisting of 4 l of PCR product (ϳ500 ng), 0.5 to 1 l of 32 P-labeled probe (ϳ5 ng), 200 mM NaCl, 10 mM Tris-HCl (pH 8.0), and 2 mM EDTA. The reaction mixture was denatured at 95°C for 5 min, allowed to anneal at 55°C for 2 h, and loaded onto a 6% native polyacrylamide mutation detection enhancement gel (Cambrex, Rockland, ME). Heteroduplexes and homoduplexes were separated by electrophoresis at 650 V for 16 h. Gels were vacuum dried at 80°C on filter paper and exposed to X-ray films for 2 h or overnight.
RESULTS
Phylogenetic analysis of envelope 1 gene sequences from probes, HCV reference strains, and clinical samples. Figure 1 shows sequence alignments (A) for the five HCV subtypespecific probes used in the present study and phylogenetic analysis of probe sequences (B) along with E1 sequences of 44 clinical samples genotyped by the HMA technique (see below) and HCV reference strains. The 438-bp probe fragments covered the carboxyl terminus of core and the amino-terminal two-thirds of E1. Phylogenetic analysis of the region revealed five divergent groups, with all isolates easily classified into one of the five HCV subtypes under study (1a, 1b, 2a, 2b, or 3a). Concordance between core/E1 genotyping and phylogenetic analysis was 100%.
Specificity and sensitivity of probe hybridization analysis. Figure 2 demonstrates HCV genotype determination by the HMA technique. In separate reactions, each of the five isotope-labeled probes was hybridized to colinear RT-PCR products derived from the sera of subjects with known HCV infections by genotypes 1a (lane 2 of all panels), 1b (lane 3 of all panels), 2a (lane 4 of all panels), 2b (lane 5 of all panels), or 3a (lane 6 of all panels), and nondenatured hybridization products were electrophoresed into mutation detection enhancement gels. Fig. 2A through E demonstrate gel shift profiles using the genotype 1a, 1b, 2a, 2b, and 3a probes, respectively. Lane 1 of panels A through E demonstrates the homoduplex control for each subtype-specific probe (hybridized to the unlabeled version of itself). Heteroduplexes were observed with retarded migration distances relative to the homoduplex control whenever a sample of known subtype was hybridized to the corresponding subtype-specific probe (Fig. 2A, Negative results occurred whenever a subtype-specific probe was hybridized to RT-PCR products with a different HCV subtype, with one exception: heteroduplexes with a much greater degree of retarded migration were also formed when the subtype 1b sample was hybridized to the 1a-specific probe ( Fig. 2A, lane 3) or vice versa (Fig. 2B, lane 2) , resulting in a secondary shift migrating near the top of the gel. Both primary and secondary shifts were observed when either genotype 1a probe (Fig. 2A, lane 7) or genotype 1b probe (Fig. 2B, lane 7) was hybridized to a mixture of 1a and 1b samples at a 1:1 ratio. The secondary heteroduplex shift pattern between genotypes 1a and 1b likely resulted from cross-hybridization, since these subtypes are more closely related than other HCV subtypes. Genotype 1a and 1b shift patterns were easily distinguishable.
In this assay, negative results in a single reaction (gel lane) only prove that a specific subtype is not detectable: they do not indicate that the specimen is negative for HCV RNA. The doublet band pattern observed in some lanes (e.g., Fig. 2B , lane 3), but not others (e.g., Fig. 2A, lane 2) , results from labeling of both strands of the DNA probe with 32 P, which is necessary to optimize assay sensitivity. In most instances, probe hybrids from opposite DNA strands comigrate as a single band under the gel conditions used; however, doublet banding may occur, and further resolution requires cloning and reanalysis of purified target DNA (data not shown).
The sensitivity of HMA genotyping was investigated by mixing purified HCV RNA of different subtypes at various concentrations and assaying mixtures of RNA against all five probes described above. Mixing experiments were performed for all possible combinations of subtype-specific RNA and probes at concentration ratios of 1:10, 1:100, and 1:1,000. Secondary (diluted) HCV subtype RNA was consistently detected at 1% of the concentration of primary (undiluted) subtype RNA. Figure 3A illustrates a representative experiment showing consistent detection of subtype 1a target using the 1a-specific probe in the presence of decreasing amounts of subtype 2b target. In Fig. 3B , the same dilution series was probed for subtype 2b target with 2b probe; lanes 2 and 3 of Fig. 3B show detection of the subtype 2b target at 10% and 1% of the concentration of background subtype 1a target, respectively. In Fig. 3C , subtype 1a target was diluted in the presence of a constant amount of subtype 1b target. Lanes 2 and 3 of Fig. 3C show detection of subtype 1a target at 10% and 1% of the concentration of subtype 1b target, respectively. In contrast, conventional 5Ј-UTR-based genotyping assays poorly discriminate second genotypes at concentrations of 10% of the total population (data not shown). HMA analysis of serum samples defined as multiple-subtype infections by 5-RFLP analysis. As part of an ongoing population-based study involving subjects with documented chronic hepatitis C (23), 769 serum specimens from 374 subjects were tested for HCV genotype by 5Ј-RFLP analysis. In 153 subjects, specimens with HCV genotype results were available from more than one time point. Multiple-subtype HCV infections were identified in 21 (5.6%) of the 374 subjects, while HCV genotype switching between different time points was detected in 7 (4.6%) of the 153 subjects with more than one serum specimen, suggesting that superinfection with a new HCV subtype had occurred. The data are summarized according to risk factor for HCV infection in Table 2 . It is important to note that, based on 5Ј-RFLP results, risk factor for HCV infection did not influence the likelihood of having multiple HCV infections, since the risk was 7.1% in intravenous drug users (IDUs) compared to 5.8% in subjects with only blood transfusion as a risk factor for HCV acquisition (Table 2 ). This discrepancy was the primary reason for developing the HMA method as a confirmatory test for HCV genotype assignment.
Extra samples were available and further genotyped by core/E1 probe hybridization using the full panel of HCV subtype probes (1a, 1b, 2a, 2b, and 3a) for each specimen (Table  3) . Of the 21 samples that were determined by 5Ј-RFLP analysis to harbor multiple-subtype HCV infections, only 1 specimen was confirmed to have two different HCV subtypes by core/E1 probe hybridization, while the remaining 20 samples contained only a single HCV subtype. Of the seven subjects that were determined by 5Ј-RFLP analysis to switch HCV subtype over time, five subjects had specimens that were genotyped differently by HMA versus 5Ј-RFLP analysis. Based on HMA results, HCV subtype switching was not apparent in these five subjects (Table 3) . Thus, over 80% of mixed-subtype HCV infection results defined by 5Ј-RFLP analysis were not reproduced using the more sensitive HMA technique. All three HMA-confirmed multisubtype HCV infections occurred in subjects with documented IDU (Table 3) .
HMA testing for multiple-subtype HCV infections in tissue compartments. In a recent study, Di Liberto et al. reported that multiple-subtype HCV infections frequently occur in a tissue-restricted fashion in subjects with chronic hepatitis C. In an attempt to confirm this finding, HCV genotypes were determined by core/E1 probe hybridization analysis in 70 tissue compartments from 23 subjects with end-stage hepatitis C who were classified as having HCV genotype 1 infections based on 5Ј-RFLP analysis of serum specimens at an earlier date (Table  4 ). All 70 tissue compartment samples from the 23 subjects, including serum (n ϭ 19), liver (n ϭ 22), lymph node (n ϭ 16), and PBMC (n ϭ 13), were positive for HCV RNA. All 70 samples were analyzed by both 5Ј-RFLP and the HMA technique using the full panel of HCV subtype-specific probes (1a, 1b, 2a, 2b, and 3a). Using the 5Ј-RFLP assay, 2 of 23 subjects had evidence of multiple-subtype HCV infections. Using the HMA assay, there was no evidence of a second HCV subtype a Other risk factors include greater than 10 lifetime sexual partners, sexual partners with history of IDU, tattooing, piercing, intranasal cocaine use, household contact with HCV, and unknown.
in any of the tissue compartments (0 of 70 specimens [0%]). Furthermore, the same HCV subtype (either 1a or 1b) that was detected in the serum compartment was also detected in the liver, lymph node, and PBMC compartments from the same subject, without exception (23 of 23 subjects). Figure 4 shows the HMA results of serum and tissue compartment samples from the two subjects with mixed-subtype HCV infections (1a and 1b) based on 5Ј-RFLP analysis using the panel of five subtype-specific probes (Fig. 4A through E) . As shown in the figure, both subjects were infected with HCV subtype 1a in all seven compartments (Fig. 4A) , and all compartments were negative for infections with subtypes 1b (B), 2a (C), 2b (D), and 3a (E). E1 gene nucleotide sequencing confirmed the genotyping results from the HMA test in seven of seven discordant samples (data not shown).
DISCUSSION
HCV demonstrates nucleotide variability throughout its entire genome, a fact that has important implications not only for choosing therapeutic regimens, but also for understanding hepatitis C pathogenesis. Extensive distribution of HCV genomes throughout nonhepatic reservoirs has been described, and some evidence supports the hypothesis that different HCV variants may acquire specific tropism for hepatic versus nonhepatic reservoirs. However, the issue remains controversial, and one of the major limitations toward reaching consensus regarding this aspect of HCV virology is that there are many technical approaches described for assessing HCV genotype and quasispecies diversity, and some of these methods are naturally superior to others. The contributions of the present study are (i) description of a sensitive and specific assay (HMA) for evaluating the presence of mixed-genotype and -subtype HCV infections in serum and tissues, (ii) generation of additional data on specimens labeled as containing mixedgenotype HCV infections based on 5Ј-UTR analysis, and (iii) generation of data on the question of tissue sequestration of HCV subtypes using the HMA technique. The HMA technique failed to verify over 75% of multiple-subtype HCV infections in our field study specimens and also failed to verify the hypothesis that subjects with chronic hepatitis C frequently harbor infections with a second HCV genotype or subtype in nonhepatic compartments (11) .
The HMA technique developed for the present study can detect secondary HCV subtypes at 1% of the concentration of primary subtypes. This level of sensitivity is roughly 10-fold greater than present methods of 5Ј-UTR analysis. Direct sequencing of less-conserved HCV genes, such as E1 or NS5B, is considered the "gold standard" of genotyping (20) ; in the present study, accuracy of the HMA technique versus E1 gene sequencing was 100% (n ϭ 44 samples). Performing the present study using the sequencing approach would require analysis of 100 clones per specimen to reach the sensitivity provided by HMA.
There are several limitations of the 374-subject field study, including the fact that specimens were not systematically evaluated by HMA. Therefore, we may have missed a significant number of mixed-subtype infections not detected by the lesssensitive 5Ј-RFLP technique. The HMA technique is laborious and expensive, and the question of 5Ј-UTR test accuracy for assigning HCV genotypes has been more efficiently addressed by phylogenetic analysis of HCV coding regions. Other investigators, using a sequencing approach, have arrived at a similar conclusion to the present study relative to the frequency of mixed-genotype HCV infections in the peripheral circulation. One consistent error in conventional 5Ј-UTR-based assays is between subtypes 1a and 1b; about 20% of subtype 1a isolates were misclassified as subtype 1b due to differences of only a single nucleotide (6, 7) . In other regions of the world, genotyping errors may confuse the classification of genotype 1 versus 6, 2a versus 2c, and possibly other situations. Based on 5Ј-UTR results in the 374-subject cohort, 7.5% of the population had either mixed-subtype HCV infections or switching of HCV subtypes over time within the same patient (implying subtype superinfection). However, the frequencies of these two virological events were not different between populations with multiple HCV exposures (i.e., IDUs) versus single HCV exposures (i.e., blood transfusion recipients). When the data were generated using HMA, mixed-subtype infections and subtype-switching events were rare (0.8% of subjects) and were exclusively found in subjects with documented risk of multiple HCV exposures via the IDU route. Although insignificant from a statistical perspective, the association between high-risk behavior and confirmation of multiple-subtype HCV infections by HMA reinforces our laboratory-based conclusions regarding genotyping accuracy.
Despite the advantages of HMA, sensitivity is still insufficient to rule out the possibility that secondary subtype infections occur at very low levels in high-risk groups, below the assay detection limit. Furthermore, very few specimens were assayed over time, so transient or oscillating mixed infections could have been missed. Finally, quasispecies sampling is most accurate when viral titers are high, which was not always the case in tissues such as PBMCs. Therefore, HMA testing may have missed some multiple-subtype infections because of sampling bias.
As alluded to above, Di Liberto et al. reported that up to 24% of immunocompetent hepatitis C subjects were coinfected by two or more HCV genotypes or subtype variants (11) . In the present study, 100% of PBMC samples were positive for HCV RNA. Serum contamination causing a PBMC signal was ruled out by extensive washing, monitoring of wash fractions for HCV RNA, and protease treatment of representative samples. Furthermore, sequencing of the envelope 2 hypervariable region indicated frequent differences in PBMC-associated genomes compared to serum-associated genomes (data not shown), confirming that PBMC signal was not derived from serum. HCV subtypes in the PBMCs were identical to that observed in serum, lymph nodes, or liver in 100% of cases, arguing against tissue sequestration of second subtype HCV infections. Our study patients differed from those studied by Di Liberto in that all had advanced-stage disease, and perhaps HCV dissemination differed for that reason.
Previous reports of HCV subtype sequestration have used 5Ј-UTR analysis to assign HCV genotypes (11, 33) . The 5Ј- FIG. 4 . HMA genotype analysis of the serum and tissue specimens from two subjects with mixed-subtype HCV infections (1a and 1b) based on 5Ј-RFLP analysis. Samples from seven different tissue compartments of the two subjects were each analyzed using the five HCV subtype-specific probes (1a, 1b, 2a, 2b, and 3a). UTR, more conserved than other regions of the viral genome, is almost exclusively used for routine detection and genotype assignment of HCV in clinical assays (35) . Whereas sequence conservation is desirable for consistent detection of HCV across genotypes, high conservation makes genotype characterization less reliable, because spurious point mutations can change assay results. Tissue sequestration of viral variants from the same quasispecies, with different 5Ј-UTR sequences in different tissues, has been previously demonstrated; data indicate that the phenomena may be important for tissue-specific translational regulation (14) . For this reason, reports of sequestration of different HCV subtypes in different tissue compartments need to be validated by independent methods targeting different regions of the viral genome and in different patient populations.
In summary, the present study describes a new HMA method for assessing mixed-subtype HCV infections. HMA was capable of detecting second-subtype HCV infections at 1% the level of primary subtype infections. HMA also showed 100% concordance with nucleotide sequencing for assigning HCV subtype. Surprisingly, over 95% of "mixed-genotype" results based on 5Ј-UTR analysis in a field study were not reproducible using the HMA technique. Therefore, results from studies of HCV subtypes based on 5Ј-UTR analysis alone must be interpreted with caution.
